PMID- 37403746
OWN - NLM
STAT- MEDLINE
DCOM- 20230915
LR  - 20230916
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 12
IP  - 16
DP  - 2023 Aug
TI  - Effectiveness, safety, and impact on quality of life of eribulin-based therapy in 
      heavily pretreated patients with metastatic breast cancer: A real-world analysis.
PG  - 16793-16804
LID - 10.1002/cam4.6301 [doi]
AB  - INTRODUCTION: Eribulin is currently recommended for the treatment of patients 
      with metastatic breast cancer (MBC) pre-treated with taxanes and anthracyclines. 
      The aim of the present study was to evaluate the effectiveness and safety of 
      eribulin and its impact on health-related quality of life in heavily pre-treated 
      patients with MBC. METHODS: Data from MBC patients who had received 
      eribulin-based therapy at Beijing Cancer Hospital between January 2020 and July 
      2022 were analyzed retrospectively. Progression-free survival (PFS), overall 
      survival (OS), objective response rate (ORR), disease control rate (DCR), adverse 
      effects (AEs) and health-related quality of life (HRQoL) were assessed. RESULTS: 
      Data from 118 patients who had received eribulin to treat MBC were included. 
      Median PFS was 4.2 months and median OS had not been reached. The ORR was 13.6% 
      (16/118) and DCR was 75.4% (89/118). The median PFS in patients who received 
      eribulin in second-line (26/118), third-line (29/118), or fourth-line or later 
      (63/118) was 4.5, 4.2, and 3.9 months, respectively. The median OS in patients 
      who received eribulin in third- or later line (n = 92) was 14.1 months. Patients 
      who received eribulin combination therapy had a significantly longer median PFS 
      compared with those who received eribulin monotherapy (4.5 vs. 3.4 months, 
      p = 0.007) and there was a trend towards a longer median OS (not reached vs. 
      12.1 months). The most common grade 3-4 adverse events were neutropenia (22.9%), 
      leukocytopenia (13.6%) and asthenia/fatigue (8.5%), without significant 
      differences in safety between eribulin monotherapy and combination therapy. 
      Quality of life was similar in patients who received eribulin monotherapy and 
      combination therapy, except for cognitive function and nausea and vomiting 
      symptoms, which were better with combination therapy. CONCLUSIONS: The present 
      study suggests that eribulin-based therapy is an effective treatment option and 
      well tolerated for heavily pre-treated patients with MBC. Eribulin combination 
      therapy might improve PFS and HRQoL compared with eribulin monotherapy.
CI  - (c) 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Gui, Xinyu
AU  - Gui X
AUID- ORCID: 0000-0002-0589-8732
AD  - Key laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Beijing, China 100142, China.
FAU - Liang, Xu
AU  - Liang X
AUID- ORCID: 0000-0003-2802-4146
AD  - Key laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Beijing, China 100142, China.
FAU - Li, Huiping
AU  - Li H
AUID- ORCID: 0000-0002-3331-647X
AD  - Key laboratory of Carcinogenesis and Translational Research (Ministry of 
      Education/Beijing), Department of Breast Oncology, Peking University Cancer 
      Hospital & Institute, Beijing, China 100142, China.
LA  - eng
PT  - Journal Article
DEP - 20230705
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - LR24G6354G (eribulin)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Breast Neoplasms/pathology
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - *Neutropenia
PMC - PMC10501238
OTO - NOTNLM
OT  - eribulin
OT  - heavily pre-treated
OT  - metastatic breast cancer
OT  - real world study
COIS- All the authors declare that they have no competing interests.
EDAT- 2023/07/05 06:42
MHDA- 2023/09/15 06:43
PMCR- 2023/07/05
CRDT- 2023/07/05 05:43
PHST- 2023/05/25 00:00 [revised]
PHST- 2023/02/07 00:00 [received]
PHST- 2023/06/20 00:00 [accepted]
PHST- 2023/09/15 06:43 [medline]
PHST- 2023/07/05 06:42 [pubmed]
PHST- 2023/07/05 05:43 [entrez]
PHST- 2023/07/05 00:00 [pmc-release]
AID - CAM46301 [pii]
AID - 10.1002/cam4.6301 [doi]
PST - ppublish
SO  - Cancer Med. 2023 Aug;12(16):16793-16804. doi: 10.1002/cam4.6301. Epub 2023 Jul 5.